Table 3.
Predicted cost-effectiveness of Wolbachia at the end of the programme. Accelerated and sequenced programmes correspond to completing roll out in 3 and 10 years, respectively. Only eligible areas (at least 1000 people per km2) receive treatment. All costs are in present value 2018 US dollars. All costs and benefits are discounted at a rate of 3% per annum. Net costs include cost offsets for medical and societal benefits from averted cases. Figures in brackets represent 95% uncertainty intervals
| Committed area | Scale-up scenario | |||
|---|---|---|---|---|
| Yogyakarta City | Remaining Yogyakarta SAR | Jakarta | Bali | |
| Accelerated introduction | ||||
| Gross $/DALY averted | $ 1831 (892–4522) | $ 2133 (1048–4953) | $ 1566 (857–3244) | $ 2996 (1599–6778) |
| Net $/DALY averted (including averted medical and societal costs) | $ − 543 (− 1419–1976) | $ - 242 (− 1275–2438) | $ − 839 (− 1500–731) | $ 671 (− 719–4219) |
| Sequenced introduction | ||||
| Gross $/DALY averted | $ 1519 (737–3732) | $ 2168 (1064–5042) | $ 1111 (611–2307) | $ 2366 (1264–5379) |
| Net $/DALY averted (including health sector and societal costs) | $ − 862 (− 1572–1185) | $ − 210 (− 1258–2528) | $ − 1280 (− 1772–− 207) | $ 64 (− 1050–2834) |